Pfizer (NEOE:ZPFE) Short-Term Debt: C$5,337 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEOE:ZPFE Pfizer Inc NEOE:ZPFE
57 GF Score
Price C$9.51
GF Value C$9.97
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Short-Term Debt?

Pfizer NEOE:ZPFE 57 Short-Term Debt is C$5,337 Mil as of Mar. 2026. GuruFocus rates NEOE:ZPFE with a GF Score™ of 57/100 and a GF Value™ of C$9.97 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Short-Term Debt for the quarter that ended in Mar. 2026 was C$5,337 Mil.

Pfizer's quarterly Short-Term Debt declined from Sep. 2025 (C$5,953 Mil) to Dec. 2025 (C$4,351 Mil) but then increased from Dec. 2025 (C$4,351 Mil) to Mar. 2026 (C$5,337 Mil).

Pfizer's annual Short-Term Debt declined from Dec. 2023 (C$13,880 Mil) to Dec. 2024 (C$9,896 Mil) and declined from Dec. 2024 (C$9,896 Mil) to Dec. 2025 (C$4,351 Mil).

Pfizer Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Pfizer Short-Term Debt Related Terms

Pfizer Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Pfizer's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Short-Term Debt Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,868.48 3,985.84 13,880.19 9,895.97 4,350.94

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,418.57 5,871.77 5,952.77 4,350.94 5,337.08
NEOE:ZPFE
57GF Score
Pfizer Inc NEOE:ZPFE
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of C$5,337 Mil mean?
Pfizer (NEOE:ZPFE) has a Short-Term Debt of C$5,337 Mil as of Mar. 2026.
Is Pfizer's Short-Term Debt too high?
Pfizer's current Short-Term Debt is C$5,337 Mil. Overall, Pfizer has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Short-Term Debt compare to GILD and BMY?
Pfizer's Short-Term Debt of C$5,337 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Pfizer's current Short-Term Debt is C$5,337 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (NEOE:ZPFE) is currently considered Fairly Valued. The stock's GF Value™ is C$9.97, compared to a current price of C$9.51 — trading 4.6% below its estimated fair value. The current Short-Term Debt is C$5,337 Mil. Pfizer's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Pfizer (NEOE:ZPFE), the current Short-Term Debt is C$5,337 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (NEOE:ZPFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of C$9.51 is trading 4.6% below its estimated GF Value™ of C$9.97. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for NEOE:ZPFE:

  • Short-Term Debt: C$5,337 Mil
  • GF Value™: C$9.97 vs. price of C$9.51 (4.6% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the NEOE:ZPFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
57GF Score

Get the complete analysis for NEOE:ZPFE

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.51
Price
C$9.97
GF Value